1Mrozek K, Marcucci G,Nicolet D, et al. Prognosticsignificance of the European Leukemia Net standardizedsystem for reporting cytogenetic and molecular alterationsin adults with acute myeloid leukemia[ J]. J Clin Oncol,2012,30(36) : 4515 -4523.
3Gibson BE, Wheatley K, Harm IM, et al. Treatmentstrategy and long-term results in paediatric patientstreated in consecutive UK AML,trials [ J] . Leukemia,2005,19(12) : 2130 -2138.
4Kalaycio M,Advani A, Pohlman B, et al. Timedsequential induction chemotherapy and risk-adaptedpostremission therapy for acute myelogenous leukemia[J]. Am J Hematol,2008,83(ll) : 831 -834.
5Kantarjian HM,Erba HP, Claxton D,et al. H study ofclofarabine monotherapy in previously untreated olderadults with acute myeloid leukemia and unfavorableprognostic factors[ J] . J Clin Oncol,2010,28 (4) : 521 -523.
6Faderl S, Ravandi F,Huang X,et al. A randomizedstudy of clofarabine versus clofarabine plus low-dosecytarabine as front-line therapy for patients aged 60 yearsand older with acute myeloid leukemia and high-riskmyelodysplastic syndrome [ J]. Blood,2008,112 ( 5 ):1638 -1645.
8Larson RA,Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloidleukemia in first relapse using Mylotarg ( gemtuzumabozogamicin) [ J]. Leukemia,2002,16(9) : 1627 - 1636.
10Knapper S,Burnett AK, Littlewood T, et al. A phase 2trial of the FLT3 inhibitor lestaurlinib( CEP701 ) as first-line treatment for older patients with acute myeloidleukemia not considered fit for intensive chemotherapy[J]. Blood, 2006,108(10) : 3262 -3270.
3Litzow MR. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol, 2007;14: 130 - 137.
4Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother, 1977 ; 12 : 298 - 300.
5Huang MT. Hardngtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol, 1975 ;11:511 -519.
6Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 1991 ;77 : 1666 - 1674.
7Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 1992;79:313-319.
8Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase HI trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group study. J Clin Oncol, 1992;10:1103 -1111.
9Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th ). Lyon, France: IARC Press; 2008.
10O'Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Nail Compr Canc Netw, 2011 ;9:280 -317.
